Skip to main content

Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.

Keywords: Protein tyrosine kinases; SH2; SH3; Src kinases; inhibitor; nonpeptide; peptidomimetic; progress

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986710790827861

Affiliations: Department of Biochemistry and Molecular Biology, Faculty of Basic Medical Sciences, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, P.R., China.

Publication date: April 1, 2010

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more